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Abstract: OBJECTIVE To estimate the extent of and the reasons for ineligibility in randomized controlled
trials (RCTs) of systemic sclerosis (SSc) patients included in the EUSTAR database, and to determine
the association between patient’s features and generalizability of study results. METHODS We searched
Clinicaltrials.gov for all records on interventional SSc-RCTs registered from January 2013 to January 2018.
Two reviewers selected studies, and information on the main trial features were retrieved. Data from 8046
patients having a visit in the EUSTAR database since 2013 were used to check patient’s eligibility. The
proportion of potentially eligible patients per trial, and the risk factors for ineligibility were analyzed.
Complete-, worst- and best-case analyses were performed. RESULTS Of the 37 RCTs included, 43%
were conducted in Europe, 35% were industry-funded, and 87% investigated pharmacological treatments.
Ninety-one percent of 8046 patients included could have participated in at least one RCT. In complete-
case analysis, the median [range] proportion of eligible patients having the main organ complication
targeted by each study was 60% [10-100] in the overall sample of trials, ranging from 50% [32-79] for trials
on skin fibrosis to 90% [34-77] for those targeting Raynaud’s phenomenon. Among the criteria checked,
treatment- and safety-related but not demographic were the main barriers to patient’s recruitment. Older
age, absence of Raynaud’s phenomenon, and lower mRSS were independently associated with the failure
to fulfill criteria for any of the included studies. CONCLUSIONS Patient’s representativeness in SSc-
RCTs is highly variable and is driven more by treatment- and safety-related rather than demographic
criteria.
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Key messages
- A poor representativeness of real-life patients in clinical trials is a major factor 
limiting the generalizability of study results.
- Patient’s representativeness in SSc-RCTs is highly variable across studies. 
- Older age, absence of Raynaud’s phenomenon, and lower mRSS are risk 
factors for SSc-RCTs inelegibility.  
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Objective. To estimate the extent of and the reasons for ineligibility in randomized 
controlled trials (RCTs) of systemic sclerosis (SSc) patients included in the EUSTAR 
database, and to determine the association between patient’s features and 
generalizability of study results.
Methods. We searched Clinicaltrials.gov for all records on interventional SSc-RCTs 
registered from January 2013 to January 2018. Two reviewers selected studies, and 
information on the main trial features were retrieved. Data from 8046 patients having 
a visit in the EUSTAR database since 2013 were used to check patient’s eligibility. The 
proportion of potentially eligible patients per trial, and the risk factors for ineligibility 
were analyzed. Complete-, worst- and best-case analyses were performed.  
Results. Of the 37 RCTs included, 43% were conducted in Europe, 35% were 
industry-funded, and 87% investigated pharmacological treatments. Ninety-one 
percent of 8046 patients included could have participated in at least one RCT. In 
complete-case analysis, the median [range] proportion of eligible patients having the 
main organ complication targeted by each study was 60% [10-100] in the overall 
sample of trials, ranging from 50% [32-79] for trials on skin fibrosis to 90% [34-77] for 
those targeting Raynaud’s phenomenon. Among the criteria checked, treatment- and 
safety-related but not demographic were the main barriers to patient’s recruitment. 
Older age, absence of Raynaud’s phenomenon, and lower mRSS were independently 
associated with the failure to fulfill criteria for any of the included studies.  
Conclusions. Patient’s representativeness in SSc-RCTs is highly variable and is 
driven more by treatment- and safety-related rather than demographic criteria. 



































































































































































Systemic sclerosis (SSc) is a rare, systemic autoimmune disease characterized by 
vasculopathy, dysregulation of the immune system and fibrosis (1). Due to the 
rarity of the disease, the heterogeneity of clinical phenotypes (2), and the difficulty 
to develop reliable outcome measures, conducting research in SSc is challenging 
(3,4).  
Randomized controlled trials (RCTs) are the gold standard to estimate the efficacy 
of medical interventions (5), and are conducted under rigorous conditions. Aside 
from patient randomization, the assessment of adherence to protocol, the use of 
validated statistical methods, and the careful choice of eligibility criteria are 
necessary to minimize the occurrence of bias and to produce reliable results within 
the sample of individuals participating in the study (internal validity)(6). However, 
if the recruited subjects are not sufficiently similar in clinically relevant 
characteristics to those seen in daily practice, the applicability of study results to a 
target population can be impaired (7,8). This means that individuals 
underrepresented in trials could be prevented from receiving the benefits of a new 
drug or, conversely, be exposed to unexpected harms. The extensive use of 
unnecessary, and too restrictive eligibility criteria, is the main driver of poor 
generalizability of RCTs results (9). This issue has been shown to be common 
across different medical specialties, but few data are available for SSc (10). The 
only study in SSc, published more than 10 years ago (11), found that only a 
minority of SSc patients could have been suitable to enter in RCTs, but reasons of 
such low eligibility rate were not investigated. Considering the importance of 
ensuring the highest number of SSc patients to be potentially enrolled and 
therefore benefit from interventions investigated in clinical trials, we planned this 


































































































































































study: to estimate to what extent SSc patients enrolled in the EUSTAR database 
could have participated in RCTs conducted over 5 years; to determine patient’s 
characteristics associated with RCT non-eligibility; and to analyze geographical 
differences in patient’s eligibility. 
Methods
Search, data collection and definition of eligibility criteria in registered RCTs 
On 28 February 2018, we searched on Clinicaltrials.gov (12) all records of 
interventional SSc-RCTs registered from January 2013 through January 2018. We 
used the terms ‘systemic sclerosis’ OR ‘scleroderma’ OR ‘SSc’. We defined as 
interventional a study in which participants are assigned to groups receiving 
therapeutic intervention/treatment as determined by protocol. We excluded 
fundamental research, diagnostic and cost-effectiveness studies, and RCTs for which 
the EUSTAR database lacked the items needed to identify the main condition 
investigated (e.g. sleep disorders). Two reviewers (MI, MJ) independently checked the 
studies against the pre-specified criteria and extracted data by using a standardized 
form. The complete list is in online file. For both tasks, consensus was reached by 
discussion. A third reviewer was available in case of unresolved disagreement. The 
following study characteristics were collected: country, funding, phase of development, 
planned sample size, type of intervention, type of comparator (placebo, active 
intervention, usual care, or no intervention). A study was considered being industry-
funded if the sponsor, as defined in the glossary of ClinicalTrials.gov (12), was industry. 
Eligibility criteria were extracted for each study. Exclusion criteria were reformulated to 
obtain the correspondent inclusion criteria. For example, a criterion excluding patients 
with a serum creatinine >2.0 mg/dl, was rephrased in an equivalent criterion including 
patients with a creatinine 2.0 mg/dl. Then, each criterion was classified in one of the 


































































































































































following categories: characteristics of the disease: defining clinical parameters of the 
disease being studied; treatment: concerning future, previous or current drug intake, 
or surgery; safety: organ function, laboratory test and co-morbidity requests that 
ensure the safety of the participants to enter the trial; demographic criteria: related to 
age, sex, ethnicity; ethical and administrative: attempting to ensure conformity with 
legal and ethical norms of human experimentation and functioning of the study (9). 
Trials were grouped according to the SSc organ manifestation investigated (skin 
fibrosis, interstitial lung disease [ILD], digital ulcers, Raynaud’s phenomenon (RP), 
gastrointestinal tract, pulmonary hypertension, kidney) (13). Creatinine clearance was 
obtained from serum creatinine values by Cockcroft-Gault formula (14).
Data analysis: description of EUSTAR database and trial eligibility 
assessment in target population
The structure of the EUSTAR database and minimum essential dataset have been 
described previously (15, 16). Local ethic committee permission for each EUSTAR 
center, and patient written informed consent were obtained prior to EUSTAR 
enrolment, as required according to national law(approval from the CCER – 
Commission cantonale d’étique de la recherche -  number 09/022 for Geneva 
University Hospitals). Trial eligibility was checked for SSc patients having at least one 
visit in database since 2013. We restricted the study to patient’s visits recorded after 
2013 to evaluate representativeness in the same time span trials would have been 
potentially conducted. Number of eligibility criteria with no information in EUSTAR 
within each category (e.g. ethics) were collected, reported for each study, and 
considered to be always fulfilled. Criteria requiring the discontinuation of one or more 
drugs or having a stable dose before enrolment, were also considered always fulfilled. 
For each trial, we calculated the proportion of potentially eligible patients (i.e. fulfilling 


































































































































































all criteria at each given visit after 2013) for those with no missing data (complete-case 
analysis). We then adjusted for missing data by performing a sensitivity analysis 
imputing criterion as not fulfilled (worst-case scenario) or fulfilled (best-case scenario). 
We then conducted subgroup analyses to identify the rate of (in)eligibility a) among 
those fulfilling for each trial the ‘disease characteristics’ criteria (e.g., patients with 
digital ulcers for trials on digital ulcers), to provide an estimate of representativeness 
in the sample of patients to whom the intervention would have been delivered; and b) 
only in countries enrolling at least 100 patients. 
Reasons for ineligibility were reported. The main features of patients who resulted to 
be always ineligible (‘never eligible’) in overall sample of studies and within each 
category of trial vs. those eligible in at least one RCT (‘ever eligible’) were compared. 
Data analysis
Analyses were performed using R 3.3.2. statistical software (R Development Core 
Team, Vienna, Austria). For categorical variables, data were presented as frequencies 
and percentages. Continuous variables were expressed as median [interquartile 
range]. Factors associated with trial ineligibility in all studies, and in subgroups of RCTs 
grouping more than 3 studies (skin fibrosis, ILD, RP) were identified by univariable and 
multivariable logistic regression model.  
Results
Characteristics of patients enrolled in EUSTAR database
In total, 8046 patients, 1193 (15%) males, 31% dcSSc, with a median age and disease 
duration from the onset of first non-Raynaud’s symptom of 58 (IQR 48-67) years, and 


































































































































































9 (IQR 4-15) years respectively, were studied. Main characteristics of patients at first 
available visit are summarized in Table 1.
General characteristics of trials
Among the 37 RCTs included (figure S1 in online file), 43% were conducted in Europe, 
35% were industry-funded, 86% investigated pharmacological treatments, with 
placebo as comparator in most of them (78%). Most RCTs evaluated treatments given 
for skin fibrosis or RP/digital ulcers. Table 2 shows the main features of the included 
studies.
Overall, we retrieved from Clinicaltrials.gov 575 eligibility criteria, distributed in the 
following categories: 46% safety; 29% characteristics of disease; 14% treatment; 7% 
ethical and administrative; 4% demographic. With the data available in EUSTAR 
database, we were able to check the fulfilment of 100% of demographic criteria 
(n=24/24); 90% of disease characteristics criteria (n=154/170); 58% of treatment-
related criteria (n=47/81); 26% (n=68/262) of safety-related; and no ethics or 
administrative criteria.
Estimation of eligibility 
The proportion of patients who could have entered in at least one RCT was 91% 
(n=7323) for all studies; 33% (n=2697), 24% (n=1933), 85% (n=6807), and 19% 
(n=1540) in the subgroups of studies on skin fibrosis, ILD, RP, and digital ulcers, 
respectively.  
The median proportion of eligible patients per trial (in overall and within each trial 
category) varied greatly, being 11% [0.2-92] for the overall sample of studies; 7% [0.2-
62] for all the studies on skin fibrosis, 17% [11- 62] for studies on skin fibrosis recruiting 


































































































































































both lcSSc and dcSSc (n=4), 4% [0.2-11] for those including only dcSSc (n=11); 10% 
[1.5-42] for studies on ILD (n=5); 48% [14-92] for studies on RP (n=7); and 21% [2-24] 
for those on digital ulcers (n=3) (complete-case analysis) (Table 3). When we restricted 
the analysis to patients with the condition targeted by the trial, the median [range] 
proportion of eligible patients increased to 60% [10-100] in the overall sample of trials, 
ranging from 50% [32-79] for trials on skin fibrosis to 89% [34-77] for those targeting 
RP (complete-case analysis). The estimates of eligibility per trial in complete-, worst- 
and best-case analysis, are reported in Table 3. 
Barriers to recruitment and patient’s characteristics associated with lack of 
eligibility 
The analysis restricted to patients with the condition of interest for each study showed 
that demographic criteria were satisfied by >95% of patients in 87% of studies, while 
the fulfilment of treatment- and safety-related (>95% of patients in 48% and 53% of 
RCTs, respectively) criteria was lower.
Comparisons of main features of ‘never’ vs. ‘ever’ eligible patients in the whole sample 
or within each category of studies are provided in online file (complete-case).
Table 4 shows the main patient’s demographic and disease-related features 
associated with the status of ‘never eligible’, in the whole sample and within each trial 
category considered (see also Tables S1-S5 in online file). The proportion of ‘never 
eligible’ patients was quite homogeneous across centers according to their academic 
status (Figure S2), and their size (with a higher variability among those recruiting less 
than 100 patients) (Figure S3). Patients recruited by Internal Medicine centers were 
more often eligible for none of the RCT compared to other recruiting specialties centers 
(Figure S4). 


































































































































































Older patients, with a lower modified Rodnan skin score (mRSS), and with no current 
RP had the lowest chance to be recruited in any of the trials included in the analysis. 
For RCTs on skin fibrosis, main patient’s characteristics independently associated with 
the lack of criteria fulfilment were older age, longer disease duration, lcSSc subset, low 
mRSS, and the co-existence of pulmonary hypertension. For RCTs on ILD, older age, 
creatine kinase elevation and anti-centromere antibodies positivity increased the risk 
of ineligibility. Anti-Scl-70 positive patients were more likely to be eligible in studies on 
skin fibrosis and ILD (Table 4). 
Geographical differences in patient’s eligibility
Trial ineligibility was heterogeneous across countries (Figure 1 and Table 5). For RP 
studies, the rates of ‘never eligible’ patients were very low in some countries, like UK 
(1.4%), Hungary (1.4%), and Russia (3.5%), with the highest figure in Croatia (44.8%). 
Apart from a few exceptions (Denmark, Israel, Romania, Russia), the proportion of 
‘never eligible’ patients for trials on digital ulcers was homogeneously above the 75%. 
More heterogeneous was the proportion of patients across countries who could have 
never entered in skin fibrosis (from 40% in Romania to 86% in Denmark), or ILD (from 
27% in Russia to 96% in Israel) trials. No difference in never eligibility rates was found 
among those countries for which a definition of Welfare regimen was available 
(17)(details in online file, Figure S5).
Discussion
We aimed to estimate the extent of and the reasons for ineligibility in RCTs enrolling 
SSc patients over a 5-year period, and to determine factors associated with trial 
generalizability of study results. 


































































































































































We have found that the representativeness of real-world SSc patients in RCTs is highly 
variable across studies, and is driven more by treatment- and safety-related rather than 
demographic criteria, within those available in the database. The extent to which SSc 
patients could have entered trials varied according to how patient’s representativeness 
has been estimated, and to the different complications addressed by the studies. 
Globally, in a first analysis conducted on the overall sample, one of ten patients 
resulted to be eligible on average in each study, with figures different according to the 
organ manifestations assessed by the trials. We found, for example, that about half 
and less than one tenth of patients could have been recruited in studies on RP or in 
those on skin fibrosis or ILD, respectively. This finding, undoubtedly influenced by the 
different prevalence of each SSc organ manifestation, is quite similar to that detected 
by the only paper on the topic conducted more than 10 years ago, and can erroneously 
lead to conclude that the representativeness of SSc patients in RCTs is very poor (11). 
In fact, in their paper Villela et al emphasized the very high rate of patients deemed 
RCT ineligible, with the subsequent issues of poor generalizability of study results (11). 
To overcome the limitation of such approach, we have also estimated the theoretical 
eligibility rate within the subgroup of patients for whom interventions were intended to 
be potentially delivered, i.e. the eligibility of patients with digital ulcers for trials targeting 
this condition. In this second analysis, the median proportion of patients suitable to 
fulfill criteria for trials was higher (about 60%) as expected, with still some differences 
observed among the different trial groups, ranging from 50% in studies targeting the 
skin fibrosis to about 90% for those on RP. This observation firstly mitigates the 
concern about a very poor generalizability of SSc-RCTs (11), but also underlines that, 
even ‘adjusting’ for the condition of interest, the representativeness of patients in SSc-
RCTs even in our optimistic estimate is not ‘perfect’ yet. Second, the observed lower 


































































































































































inclusiveness in RCTs on skin fibrosis and ILD if compared to that recorded in digital 
ulcers or RP, would suggest that more stringent criteria, notably treatment- or safety-
related, regulate the access in the former group of studies. We can hypothesize that 
this could represent the obvious consequence of the higher potential safety concerns 
associated with the use of drugs given for these indications (mostly immunomodulatory 
drugs), versus those conceived for RP or digital ulcers (mostly vasodilators) (15).  
However, whether having a ‘perfect’ patient’s representativeness in RCTs is a realistic 
and feasible objective, and what should be the ideal cut-off to achieve to consider a 
study ‘representative enough’ of patients seen in routine care, is hard to state. In fact, 
also in daily practice, we choose not to deliver a given treatment for various reasons, 
such as the absence of an active disease (as patient enrichment in RCTs), or for the 
co-existence of comorbidities which contraindicate its use or to avoid dangerous drug 
interactions.
Therefore, establishing if and to what extent the choice of each exclusion criterion 
could have been reasonably justified on a clinical basis, or conversely mirrors the 
exaggerated need to minimize the occurrence of drop outs or adverse events, 
represents a difficult challenge. 
The availability of an international database and a large set of eligibility criteria has 
also allowed us to better depict the features of patients less likely to enter in trials and 
therefore excluded from the potential benefit coming from the interventions tested, or 
more exposed to their unwanted harms. On average, older patients, those with a less 
severe extent of skin fibrosis, and without an active RP fall within this group. The 
underrepresentation of older patients in SSc-RCTs, even though demographic criteria 
were not identified as a main barrier to patient’s enrolment, suggests that the 


































































































































































combination of factors other than demographic criteria such as comorbidities, exposure 
to previous treatment, or other safety issues, limit the access to trials to the elderly. 
Our finding is in line with reports from other specialties (18, 19) and highlights the need 
to increase the efforts to improve the recruitment also for these more vulnerable and 
frail patients in our growing older population (20). Post-approval registries can also 
contribute to fill this gap by helping to evaluate in routine care the risk/benefit ratio of 
treating the previously unexposed and vulnerable patients (21).   
Our data confirms the need to expand the core of studies for patients with lcSSc. We 
found that lcSSc subset, milder skin involvement, or anti-centromere positivity for 
studies on ILD, independently impaired the odds to take part in trials and therefore to 
potentially receive a tested treatment in the real-world. This observed lower 
inclusiveness of lcSSc patients reflects the numeric imbalance in favor of trials 
designed for the dcSSc subset. In this regard, it has been recently shown that 25% of 
RCTs registered between years 2007-2018 were not intended to be delivered to lcSSc 
patients (3). Furthermore, the paucity of studies addressing frequent and disabling 
complications seen in this subset of patients like calcinosis, gastroesophageal or 
intestinal impairment or the physical and facial consequences of SSc, further 
corroborates our observation. The lower number of studies for lcSSc, despite being 
the more frequent subset, mirrors the difficulties of designing RCTs for these patients. 
The heterogeneity of the phenotype, the varied course, ranging from a quiescent or 
slow progressing disease, the absence of validated outcome measures for some organ 
involvement, are, among others, the main barriers to conduct trials in lcSSc patients. 
The development of outcome measures for lcSSc patients is the object of an ongoing 
study (22). 


































































































































































The analysis of the geographical differences in patient’s eligibility shows that apart from 
a few exceptions, the fulfillment of criteria for trials on digital ulcers was quite 
homogeneous, while more discrepant data were recorded in the other categories. 
Capturing the real reasons underlying this finding remains a challenge since eligibility 
was similar across health care systems, size of recruiting centers, and academic 
status. Some difference was seen between internal medicine centers compared to 
specialties centers. Nevertheless, as a descriptive analysis, this information is useful 
to plan recruitment ability and estimate feasibility of clinical trial. 
Some study limitations should be acknowledged. Since we imputed as fulfilled 
unavailable criteria in EUSTAR, our results represent an optimistic estimation of trial 
eligibility. Moreover, our analysis did not incorporate all the trials registered in the 
period considered, since we could not include RCTs intended to investigate aspects 
for which we had no information in the database (e.g. sleep problems). Study 
conclusions should therefore be interpreted considering this aspect. Furthermore, the 
identification of the subgroups of patients for whom interventions were planned, was 
based on the fulfillment of the ‘Characteristics of the disease’ criteria since there is not 
a unique definition for each SSc given complication (i.e. many different possible 
definitions for ILD). This could have further led to an optimistic estimation of patient’s 
eligibility. Limitations of the analysis on geographical differences in patient 
inclusiveness should also be acknowledged. Potential reasons for this finding include: 
a real heterogeneity of SSc phenotypes in different geographical areas (23); 
differences how patients are recruited in centers/countries; the number of academic 
versus non-academic recruiting centers in each country. 
This paper has several strengths. This study is the first conducted in a large, 
international sample of real-life patients, allowing more realistic estimates of 


































































































































































(in)eligibility rates by focusing on the subgroups of patients with the peculiar clinical 
manifestation targeted by the trial. The identification of the main barrier to study 
participation and the patient’s features associated with, represents another novelty 
aspect and provides knowledge for future study design. 
In conclusion, we have shown that the proportion of SSc patients allowed to participate 
in RCTs is highly variable across studies and that while being aware of the 
unavailability of certain factors commonly used to enrich cohorts and limiting patient’s 
inclusiveness in trials, treatment-related and general safety issues represent relevant 
barriers to study participation. Despite the fact that demographic criteria permit the 
involvement of all patient ages, the elderly are still underrepresented in RCTs. 
Importantly the need of patients with lcSSc subset is still unmet. A better understanding 
and awareness of barriers to patient recruitment when designing SSc-RCTs may 
improve generalizability of results and favour the translation of RCTs efficacy results 
to real-world patients. 
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Table 1. Characteristics of SSc patients (n=8046) included in the present study. 
Characteristics
na Overall sample
Age, median (IQR), years 8042 58 (48-67)
Male sex, n, % 8046 1193 (14.8)
Body weight, median (IQR), kilograms 7017 64 (56-74)
Disease characteristics
dcSSc subset, n, % 5069 1594 (31.4)
Disease duration since first non-Raynaud 
symptom, median (IQR), years
6952 9 (4-15)
mRSS, median (IQR) 8046 4 (0-10)
Raynaud’s phenomenon, n, % 7715 7325 (94.9)
Intestinal symptoms, n, % 7733 1916 (24.8)
Puffy fingers, current, n, % 6484 2308 (35.6)
Current digital ulcers, n, % 6027 883 (14.6) 
Pulmonary hypertension by echocardiography, n, 
%
7732 889 (11.5)
DLCO/SB, median (IQR), % of predicted 5877 69 (55-82)
FVC, median (IQR), % of predicted 6188 97 (81-111)
Renal crisis, ever, n, % 7974 122 (1.5)
Laboratory parameters
Creatine-kinase elevation (>3 ULN), n, % 6500 494 (7.6)
Anti-centromere positive, n, % 6747 2842 (42.1)
Anti-topoisomerase I positive, n, % 6808 2248 (33.0)
Anti-RNA polymerase III, n, % 4560 205 (4.5)
a Number of patients with available information for each variable. IQR, interquartile range; 
mRSS, modified Rodnan skin score; SD, standard deviation; PAPsys, systolic pulmonary 
artery pressure as estimated by echocardiography; DLCO/sb, Single breath diffusing capacity 
for carbon monoxide; FVC, forced vital capacity; ULN, upper limit of normal.







































































































































































            North America 19 (51)
            Europe 16 (43)
            Asia 13 (35)
            South America 6 (16)
            Oceania 3 (8)
            Africa 2 (5)
Industry-funded 13 (35)
Type of intervention
   Pharmacologic 32 (86.5)
   Non-pharmacologic 5 (13.5)
Study design 




Active (pharmacologic) 5 (14)
Usual care 2 (5)
No intervention 2 (5)
Eligibility criteria N=575
Mean (SD) number of eligibility criteria per trial
Demographics 24 (4)
Characteristics of disease 170 (29)
Ethical and administrative 38 (7)
Treatment 81 (14)
Safety 262 (46)
Organ manifestation being evaluated*
Skin fibrosis 15 (40)
Raynaud’s phenomenon/digital ulcers 10 (27)
Interstitial lung disease 5 (13)
Gastrointestinal disease 1 (3)
Pulmonary hypertension 1 (3)




No. of patients planned to be included or included per 
study (median, IQR)
60 (32-90)
*Multiple answers were possible. IQR. Interquartile range.


































































































































































Table 3. The proportion of eligible patients per trial from overall sample and from the subgroup of 
patients with the condition of interest being investigated by each trial.








NCT02551042* (CSL Behring Sclero XIII) 62.3 [20.8-82.6] 67.6 [28.4-88.6]
NCT03068234* 11 [3.0-21.1] 79.0 [41.8-98.6]
NCT03141125* 20.5 [6.6-31.5] 33.2 [12-52.1]
NCT03365869* 14 [5.6-39.8] 32.2 [15.3-80.6]
NCT02921971§ 1.2 [0.3-3.7] 19.1 [11.8-45.9]
NCT02453256§ (focuSSced) 5.2 [2.1-8.3] 53.9 [31.8-97.7]
NCT02588625§ 11.1 [5.4-31.7] 82.6 [72.7-84.7]
NCT02283762§ 1.6 [0.4-4.5] 48.4 [33.3-100]
NCT02503644§ (FASST) 8.0 [0-8.0] 50 [0.8-92]
NCT02161406§ (ASSET) 2 [0.5-4.2] 25.9 [16-49.6]
NCT01785056§ 7.5 [6.2-10.6] 56.9 [54.4-77.8]
NCT02349009§ 0.2 [0-5.1] 20 [11.1-61.1]
NCT03274076§° (TOFA-SSc) 3.3 [0.8-6.9] 28.3 [17.4-57.4]
NCT01651143§° 4.5 [1.8-7.5] 59.5 [42.1-98.2]
NCT03398837^ (RESOLVE-1) 11.0 [7.8-36.4] 95.0 [50.6-97.3]
All skin fibrosis, median (IQR) 7.5 (2-11) 50 (28.3-67.6)
Interstitial lung disease
NCT01862926 (RECITAL) 30.0 [20.2-53.0] 76.9 [35.8-95.1]
NCT02370693 1.5 [0.6-49.6] 50 [30.1-98.1]
NCT02896205 (MYILD) 42.3 [9.3-81.1] 68.2 [17.9-96.9]
NCT02597933 10.5 [0-13.2] 33.3 [0.8-38.6]
NCT01933334 (LOTUSS) 7.5 [1.2-12.0] 72.9 [25.5-99.5]


































































































































































All ILD, median (IQR) 10.5 (4.5-36.1) 68.2 (41.6-74.9)
Raynaud’s phenomenon
NCT03027674 48.3 [46.7-59.2] 49 [47.8-59.9]
NCT01090492 65.8 [21.6-84.8] 74.2 [25.3-96.0]
NCT03058887 18.9 [3.1-48.4] 54.4 [21.4-91.0]
NCT02165111 92.0 [48.3-97.5] 92.9 [49.5-98.8]
NCT02480335 38.4 [35.5-66.1] 99.5 [99.5-99.9]
NCT02370784 (TAMER) 13.9 [7.9-26.6] 100 [0.2-73.2]
NCT02260557 88.7 [47.1-96.0] 89.5 [48.2-97.3]
All Raynaud’s, median (IQR) 48.3 (18.9-88.7) 89.5 (54.4-99.5)
Digital ulcers
NCT02356809 2.4 [0-57.7] 10 [0.1-92.1]
NCT02801305 20.6 [16.5-58.4] 86.4 [86.4-91.8]
NCT02733978 23.9 [19.1-59.5] 100 [100-100]
All digital ulcers, median (IQR) 20.6 (2.4-23.9) 86.4 (10-100)
Pulmonary hypertension
NCT03053739 (BosSilSS) 30.8 [8.3-65.8] 61.1 [30.3-98.1]
Gastrointestinal
NCT02302352 44.6 [38.6-51.4] 100 (100-100)
Renal
NCT02047708 (ZEBRA) 1.1 [0.5-3.3] 83 [81.5-87.0]
Other
NCT01733056 7.5 [6.2-10.6] 56.9 [54.4-77.8]
NCT01918904 (STS-CALC) 6.3 [1.5-50.0] 30 [29.8-54.8]
NCT02780674 63.7 [31.5-71.3] 64 [33.2-72.4]
* studies on patients with both lcSSc and dcSSc subset; § studies on patients with dcSSc only; ° 
Safety as primary outcome, mRss as secondary outcome; ^study on dcSSc patients having the 
American College of Rheumatology Combined Response Index score (CRISS) as primary 
outcome. RCTs. Randomized controlled trials; IQR, interquartile range; ILD, interstitial lung 
disease.


































































































































































Table 4. Factors associated with the ‘never eligible’ status in the whole sample of studies included and according to the disease complication 
tailored by trials. 
All trials Skin fibrosis Interstitial lung disease Raynaud’s phenomenon
Univariable Multivariable Univariable Multivariable Univariable Multivariable Univariable Multivariable
Factor OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 1.01 (1.00-1.02)* 1.02 (1.00-1.04)** 1.03 (1.02-1.03)* 1.02 (1.01-1.03)** 1.01 (1.00-1.02)** 1.01 (1.00-1.02)* 1.01 (1.00-1.02)** 1.02 (1.01-1.04)**
Male 0.83 (0.66-1.04) 0.54 (0.47-0.61)** 0.86 (0.75-0.99)** 0.83 (0.69-0.99)**
Time from first non-Raynaud 0.99 (0.98-1.01) 1.07 (1.06-1.08)** 1.03 (1.02-1.04)** 1.01 (1.00-1.02)** 1.02 (0.99-1.01) 0.98 (0.96-0.99)*
lcSSc 4.03 (2.92-5.71)** 5.41 (4.76-6.17)** 3.55 (2.59-4.91)** 1.48 (1.30-1.68)** 1.95 (1.59-2.41)** 2.04 (1.18-2.64)**
Raynaud’s phenomenon 0.20 (0.15-0.25)** 0.30 (0.13-0.80)** 0.65 (0.51-0.82)** 0.53 (0.40-0.70)** -
Current digital ulcers 0.12 (0.06-0.23)** 0.69 (0.51-0.93)** 0.67 (0.48-0.93)* 0.67 (0.48-0.95)**
mRSS 0.90 (0.89-0.92)** 0.91 (0.86-0.97)** 0.93 (0.92-0.94)** 0.94 (0.92-0.96)** 0.98 (0.97-0.98)** 0.97 (0.96-0.98)**
Creatin kinase elevation 0.93 (0.64-1.30) 0.64 (0.53-0.77)** 1.41 (1.13-1.77)* 2.02 (1.36-3.05)** 1.01 (0.77-1.31)
Renal crisis 1.12 (0.58-1.96) 0.84 (0.58-1.21) 1.22 (0.80-1.93) 1.83 (1.18-2.74)* 3.31 (1.22-8.17)*
Dyspnea any stage 0.90 (0.79-1.02) 1.00 (0.94-1.07) 0.87 (0.81-0.94)** 1.02 (0.93-1.12)
Left ventricular EF 1.01 (1.00-1.03)* 1.00 (0.99-1.01) 1.01 (1.00-1.02)** 1.01 (1.00-1.02)**
Conduction blocks 0.95 (0.70-1.26) 1.06 (0.91-1.24) 0.90 (0.77-1.07) 1.13 (0.91-1.39)
Pulmonary hypertension 1.04 (0.79-1.34) 1.99 (1.69-2.34)** 2.49 (1.69-3.71)** 1.09 (0.93-1.29) 1.41 (1.17-1.70)** 1.66 (1.02-2.65)°
Anti-Scl70 positive 0.58 (0.47-0.72)** 0.44 (0.39-0.48)** 0.72 (0.53-0.98)* 0.48 (0.43-0.54)** 0.56 (0.43-0.74)** 0.71 (0.61-0.83)**
Anti-centromere positive 1.68 (1.41-2.01)** 2.40 (2.16-2.67)** 1.94 (1.73-2.17)** 1.45 (1.12-1.89)** 1.44 (1.26-1.66)**
FVC<80% of predicted 0.72 (0.56-0.92)* 0.69 (0.61-0.78)* 0.74 (0.65-0.84)** 0.92 (0.77-1.10)
DLCO<% of predicted 0.59 (0.48-0.72)** 0.80 (0.71-0.90)* 0.80 (0.71-0.91)** 0.80 (0.71-0.91)**
Active disease 0.76 (0.71-0.81)** 0.80 (0.78-0.83)** 0.90 (0.88-0.93)** 0.94 (0.91-0.98)**
      
                   lcSSc. limited cutaneous SSc; mRSS. Modified Rodnan skin score; EF. Ejection fraction; FVC. Forced vital capacity; DLCO. Diffusing lung capacity for carbon monoxide. **p<0.001, * 
p<0.05, °0.




















































































































































Table 5. Proportion of ‘never eligible’ patients according to the country.
N of ‘never eligible’/total number of patients (%)






Belgium 13/281 (4.6) 146 (51.9) 224 (79.7) 22 (7.8) 245 (87.2)
Croatia 43/165 (26.1) 123 (74.5) 149 (90.3) 74 (44.8) 131 (79.4)
Denmark 5/114 (4.4) 98 (85.9) 102 (89.4) 8 (7.0) 82 (71.9)
France 109/823 (13.2) 534 (64.9) 695 (84.4) 166 (20.2) 690 (83.8)
Germany 92/1267 (7.3) 839 (66.2) 920 (72.6) 145 (11.4) 988 (78.0)
Hungary 3/215 (1.4) 98 (45.5) 126 (58.6) 3 (1.4) 184 (85.6)
Israel 21/167 (12.6) 143 (85.6) 261 (96.4) 43 (25.7) 116 (69.4)
Italy 153/2031 (7.5) 1369 (67.4) 1365 (67.2) 272 (13.4) 1671 
(82.3)
Poland 22/138 (15.9) 95 (68.8) 133 (96.3) 41 (29.7) 114 (82.6)
Romania 8/322 (2.5) 130 (40.4) 216 (67.1) 27 (8.4) 226 (70.2)
Russia 4/141 (2.8) 59 (41.8) 38 (26.9) 5 (3.5) 98 (69.5)
Spain 108/619 (17.4) 512 (82.7) 584 (94.3) 144 (23.2) 555 (89.7)
Switzerland 23/545 (4.2) 313 (57.4) 281 (51.5) 47 (8.6) 454 (83.3)
Turkey 13/132 (9.8) 74 (56.1) 101 (76.5) 25 (18.9) 104 (78.8)
UK 1/282 (0.35) 161 (57.1) 200 (70.9) 4 (1.4) 219 (77.6)
ILD. interstitial lung disease.


































































































































































Figure 1. Proportion of ‘never eligible’ patients across countries for each trial category. 
Legend. ILD, interstitial lung disease.
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